Journal of Environmental Health Sciences (한국환경보건학회지)

Korean Society of Environmental Health (한국환경보건학회)
권호 표지
DOI QR코드

DOI QR Code

Association of Metabolic Syndrome with Urinary Concentration of Acrolein Biomarker 3-Hydroxypropyl Mercapturic Acid (3-HPMA): Korea National Health and Nutrition Examination Survey 2020~2021

아크롤레인의 생체 지표인 3-Hydroxypropyl Mercapturic Acid (3-HPMA)의 소변 농도와 대사증후군과의 연관성: 국민건강영양조사 2020~2021

  • Hyunsik Mo (Graduate School of Urban Public Health, University of Seoul) ;
  • Sangshin Park (Graduate School of Urban Public Health, University of Seoul)
  • 모현식 (서울시립대학교 도시보건대학원) ;
  • 박상신 (서울시립대학교 도시보건대학원)
  • Received : 2024.08.05
  • Accepted : 2024.09.20
  • Published : 2024.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: There are many published studies on the association between urinary concentration of 3-hydroxypropylmercapturic acid (3-HPMA), a metabolite of acrolein, and metabolic syndrome. However, inconsistent results have been reported. Additionally, there are currently no studies that have been conducted on Koreans. Objectives: The purpose of this study is to investigate the association between the urinary concentration of 3-HPMA, a metabolite of acrolein, and metabolic syndrome. Methods: We analyzed data from 1,559 Korean adults aged 19 and older who participated in the Korea National Health and Nutrition Examination Survey from 2020 to 2021. The criteria for metabolic syndrome were based on the National Cholesterol Education Program Adult Treatment Panel III, and the concentration of urinary 3-HPMA was divided into quartiles. The least squares means of the components of metabolic syndrome were calculated based on the concentration of 3-HPMA, and logistic regression analysis was performed to provide odds ratios (OR) and 95% confidence intervals (CI). Results: The median concentration of 3-HPMA in the participants' urine was 420.02 (IQR: 690.51~257.30) ㎍/mL, and the prevalence of metabolic syndrome was 37.8%. In the comparison of quartiles, an increase in 3-HPMA concentration was associated with a higher prevalence of components of metabolic syndrome (OR: 3.05, 95% CI: 2.02~4.62). However, after adjusting for all covariates, no significant difference was found between the urinary concentration of 3-HPMA and the components of metabolic syndrome (OR: 1.38, 95% CI: 0.74~2.54). Conclusions: We did not find a significant association between the urinary concentration of 3-HPMA, a metabolite of acrolein, and metabolic syndrome.

Keywords

Acknowledgement

이 논문은 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임(NO. 2022M3J6A1084845).

References

  1. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018; 20(2): 12. 
  2. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015; 16(1): 1-12. 
  3. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35(11): 2402-2411. 
  4. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56(14): 1113-1132. 
  5. Grundy SM. Overnutrition, ectopic lipid and the metabolic syndrome. J Investig Med. 2016; 64(6): 1082-1086. 
  6. Dong R, Chang D, Shen C, Shen Y, Shen Z, Tian T, et al. Association of volatile organic compound exposure with metabolic syndrome and its components: a nationwide cross-sectional study. BMC Public Health. 2024; 24(1): 671. 
  7. Moghe A, Ghare S, Lamoreau B, Mohammad M, Barve S, McClain C, et al. Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci. 2015; 143(2): 242-255. 
  8. Hikisz P, Jacenik D. The tobacco smoke component, acrolein, as a major culprit in lung diseases and respiratory cancers: molecular mechanisms of acrolein cytotoxic activity. Cells. 2023; 12(6): 879. 
  9. Khoramjouy M, Naderi N, Kobarfard F, Heidarli E, Faizi M. An intensified acrolein exposure can affect memory and cognition in rat. Neurotox Res. 2021; 39(2): 277-291. 
  10. Bein K, Leikauf GD. Acrolein - a pulmonary hazard. Mol Nutr Food Res. 2011; 55(9): 1342-1360. 
  11. Saiki R, Park H, Ishii I, Yoshida M, Nishimura K, Toida T, et al. Brain infarction correlates more closely with acrolein than with reactive oxygen species. Biochem Biophys Res Commun. 2011; 404(4): 1044-1049. 
  12. Park YS, Taniguchi N. Acrolein induces inflammatory response underlying endothelial dysfunction: a risk factor for atherosclerosis. Ann N Y Acad Sci. 2008; 1126: 185-189. 
  13. Feroe AG, Attanasio R, Scinicariello F. Acrolein metabolites, diabetes and insulin resistance. Environ Res. 2016; 148: 1-6. 
  14. McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al. Exposure to volatile organic compounds - acrolein, 1,3-butadiene, and crotonaldehyde - is associated with vascular dysfunction. Environ Res. 2021; 196: 110903. 
  15. Conklin DJ, Barski OA, Lesgards JF, Juvan P, Rezen T, Rozman D, et al. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicol Appl Pharmacol. 2010; 243(1): 1-12. 
  16. Lei T, Qian H, Yang J, Hu Y. The association analysis between exposure to volatile organic chemicals and obesity in the general USA population: a cross-sectional study from NHANES program. Chemosphere. 2023; 315: 137738. 
  17. Yim E, Lee K, Park I, Lee S. The prevalence of metabolic syndrome and health-related behavior changes: the Korea National Health Examination Survey. Healthcare (Basel). 2020; 8(2): 134. 
  18. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al; International Diabetes Federation Task Force on Epidemiology and Prevention. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640-1645. 
  19. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract. 2007; 75(1): 72-80. 
  20. Korea Disease Control and Prevention Agency. Guidelines for indoor air quality survey and biomarker investigation of environmental hazardous substances in the Korea National Health and Nutrition Examination Survey. Available: https://knhanes.kdca.go.kr/knhanes/sub04/sub04_02_02.do?classType=4 [accessed 20 August 2024]. 
  21. Kang YH, Lee YJ, Kim HK, Yun YH, Jeong SY, Lee JS, et al. Usefulness of urinary cotinine test to distinguish smokers from nonsmokers. Korean J Lab Med. 2003; 23(2): 92-97. 
  22. Conklin DJ, Bhatnagar A, Cowley HR, Johnson GH, Wiechmann RJ, Sayre LM, et al. Acrolein generation stimulates hypercontraction in isolated human blood vessels. Toxicol Appl Pharmacol. 2006; 217(3): 277-288. 
  23. Perez CM, Hazari MS, Ledbetter AD, Haykal-Coates N, Carll AP, Cascio WE, et al. Acrolein inhalation alters arterial blood gases and triggers carotid body-mediated cardiovascular responses in hypertensive rats. Inhal Toxicol. 2015; 27(1): 54-63. 
  24. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004; 45(7): 1169-1196. 
  25. Wang B, Liu W, Yu L, Ye Z, Cheng M, Qiu W, et al. Acrolein exposure impaired glucose homeostasis and increased risk of type 2 diabetes: an urban adult population-based cohort study with repeated measures. Environ Sci Technol. 2023; 57(18): 7162-7173. 
  26. Keane KN, Cruzat VF, Carlessi R, de Bittencourt PI Jr, Newsholme P. Molecular events linking oxidative stress and inflammation to insulin resistance and β-cell dysfunction. Oxid Med Cell Longev. 2015; 2015(1): 181643. 
  27. Alwis KU, deCastro BR, Morrow JC, Blount BC. Acrolein exposure in U.S. tobacco smokers and non-tobacco users: NHANES 2005-2006. Environ Health Perspect. 2015; 123(12): 1302-1308. 
  28. Li AJ, Pal VK, Kannan K. A review of environmental occurrence, toxicity, biotransformation and biomonitoring of volatile organic compounds. Environ Chem Ecotoxicol. 2021; 3: 91-116. 
  29. Eckert E, Schmid K, Schaller B, Hiddemann-Koca K, Drexler H, Goen T. Mercapturic acids as metabolites of alkylating substances in urine samples of German inhabitants. Int J Hyg Environ Health. 2011; 214(3): 196-204.